Detailed analyses of ligand choice, linkage vector and linker length enabled the development of bitopic inhibitors of ABL1 and EGFR kinases, including an ABL1 inhibitor with enhanced activity against ...

Bristol Myers Squibb is leveraging data and AI to significantly accelerate drug discovery and improve patient health, aiming to deliver high-value medicines faster. SVP Matteo diTommaso emphasizes a ...

Designing an efficient platform is crucial for any industrial process. This design process is known as process development, and it has become increasingly important in the pharmaceutical industry at ...

UM researchers have developed a deep learning model to predict compound protein interactions. GraphBAN is an inductive graph-based approach. The model is all about discovering new drug candidates in ...

AI drug discovery is not something that can be completed by AI companies alone.To deliver new drugs to patients, it is ...

AI could cut preclinical drug R&D costs and timelines by 70%, but its real test is whether it helps deliver safe, effective medicines to patients.

AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.

Over the past year, drug discovery has gotten a massive boost from the CAS BioFinder Discovery Platform, which allows scientists to explore known and predicted data that accelerate the preclinical ...

At the heart of every biological process, from the replication of cells to the functioning of the human brain, lies the intricate world of proteins. Understanding the structure of these molecules, ...

Hello, I'm Yuki. I work as a process chemist at a pharmaceutical company.When people think of jobs in pharmaceutical companies that utilize organic chemistry, most probably think of 'drug discovery ...

AI, machine learning and big data are advancing virtual screening and precision medicine, creating opportunities in molecular modeling, docking and data integration.Dublin, Sept. 22, 2026 (GLOBE ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...